

Hertzel C Gerstein

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1471997/hertzel-c-gerstein-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

422
papers

55,533
citations

95
h-index

232
g-index

473
ext. papers

64,011
ext. citations

11.8
avg, IF

7.45
L-index

#	Paper	IF	Citations
422	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.. <i>Diabetes Care</i> , 2022 ,	14.6	2
421	Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. <i>Diabetologia</i> , 2022 , 65, 206-215	10.3	2
420	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations.. <i>Communications Biology</i> , 2022 , 5, 329	6.7	2
419	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1
418	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.. <i>Nature Genetics</i> , 2022 ,	36.3	7
417	Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. <i>Circulation</i> , 2022 , 145, 1642-1644	16.7	
416	Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. <i>Diabetes Care</i> 2022;44:684B91. <i>Diabetes Care</i> , 2022 , 45, e111-e112	14.6	
415	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
414	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021 , 16, 102382	8.9	4
413	HbA Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. <i>Diabetes Care</i> , 2021 , 44, 290-296	14.6	13
412	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021 , 42, 2565-2573	9.5	7
411	Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 594-600	2.1	1
410	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2021 , 18, 14791641211002475	3.3	1
409	Insulin Therapy: The Discovery That Shaped a Century. <i>Canadian Journal of Diabetes</i> , 2021 ,	2.1	5
408	Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. <i>JAMA Network Open</i> , 2021 , 4, e216820	10.4	5
407	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. <i>JAMA Internal Medicine</i> , 2021 , 181, 631-649	11.5	17
406	Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1926-1935	6.7	0

405	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3426-e3435	5.6	4
404	187-OR: Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in the ACCORD Trial. <i>Diabetes</i> , 2021 , 70, 187-OR	0.9	
403	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e5043-e5053	5.6	0
402	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107928	3.2	1
401	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021 , 44, 164-173	14.6	12
400	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. <i>Diabetes Care</i> , 2021 , 44, e6-e8	14.6	4
399	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
398	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e891-e898	5.6	3
397	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e34-e44	5.6	5
396	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 978-987	5.6	2
395	The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1521-e1528	5.6	4
394	Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. <i>Diabetes Care</i> , 2021 , 44, e85-e86	14.6	0
393	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1345-1351	5.6	2
392	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2021 , e14669	3.5	2
391	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	15
390	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 484-490	18.1	2
389	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	4
388	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 2359-2366	10.3	7

387	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. <i>Cardiovascular Diabetology</i> , 2021 , 20, 194	8.7	4
386	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021 , 10, e022222	6.2	2
385	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
384	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 653-662	18.1	58
383	Adolescent cognitive function and incident early-onset type 2 diabetes. <i>EClinicalMedicine</i> , 2021 , 41, 101138	13.8	1
382	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. <i>European Heart Journal</i> , 2020 , 41, 2668-2675	7.5	33
381	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , 2020 , 19, 582-590	24.1	48
380	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , 2020 , 142, 621-642	16.7	88
379	Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
378	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020 , 69, 771-783	0.9	12
377	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
376	Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 557-558	18.1	1
375	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020 , 43, 2242-2247	14.6	4
374	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals. <i>Journal of the American Heart Association</i> , 2020 , 9, e014686	6	24
373	Dulaglutide slows kidney disease in type 2 diabetes - Author's reply. <i>Lancet</i> , 2020 , 395, 559-560	40	
372	Influence of Genetic Ancestry on Human Serum Proteome. <i>American Journal of Human Genetics</i> , 2020 , 106, 303-314	11	8
371	Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e002605	5.2	4
370	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	16.7	25

369	356-OR: Effect of Dulaglutide on Kidney Function Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. <i>Diabetes</i> , 2020 , 69, 356-OR	0.9	2
368	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. <i>Diabetes</i> , 2020 , 69, 924-P	0.9	1
367	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2020 , 43, 835-842	14.6	16
366	Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. <i>ELife</i> , 2020 , 9,	8.9	8
365	130-OR: Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial. <i>Diabetes</i> , 2020 , 69, 130-OR	0.9	
364	944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up. <i>Diabetes</i> , 2020 , 69, 944-P	0.9	
363	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. <i>Diabetes Care</i> , 2020 , 43, 145-151	14.6	11
362	Novel Biomarkers for Change in Renal Function in People With Dysglycemia. <i>Diabetes Care</i> , 2020 , 43, 433-439	14.6	1
361	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 106-114	18.1	42
360	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020 , 49, 154-160	3	7
359	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. <i>Diabetes Care</i> , 2020 , 43, 3094-3101	14.6	10
358	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	8.7	1
357	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3
356	Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 184-191	2.1	1
355	Adolescent Obesity and Early-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1487-1495	14.6	36
354	The importance of randomised vs non-randomised trials - Authors' reply. <i>Lancet, The</i> , 2019 , 394, 635	40	5
353	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1299-1304 ²⁷	6.7	27
352	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019 , 42, 1159-1161	14.6	7

351	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
350	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 131-138	40	228
349	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. <i>Trends in Molecular Medicine</i> , 2019 , 25, 640-655	11.5	8
348	Dysglycemia and the Density of the Coronary Vasa Vasorum. <i>Diabetes Care</i> , 2019 , 42, 980-982	14.6	13
347	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1502-1505	6.7	1
346	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. <i>Diabetes Care</i> , 2019 , 42, 1800-1808	14.6	3
345	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinologia y Nutrición (English Ed)</i> , 2019 , 66, 467-468	0.1	
344	240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes</i> , 2019 , 68, 240-LB	0.9	
343	1506-P: Breast Cancer as a Risk Factor for New Diabetes. <i>Diabetes</i> , 2019 , 68, 1506-P	0.9	
342	254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial. <i>Diabetes</i> , 2019 , 68, 254-OR	0.9	
341	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2019 , 66, 467-468	1.3	
340	Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. <i>Nature Metabolism</i> , 2019 , 1, 1202-1208	14.6	80
339	The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 429-433	6.7	2
338	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 847-854	3.9	6
337	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. <i>Diabetes Care</i> , 2019 , 42, 142-147	14.6	15
336	Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 4-5	18.1	
335	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019 , 393, 210-211	40	56
334	A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. <i>Clinical Chemistry</i> , 2019 , 65, 427-436	5.5	8

333	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 477-482	2.1	3
332	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1326-1335	12.7	14
331	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 821-832	18.1	61
330	Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e3018	7.5	4
329	The Genetic Link Between Diabetes and Atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 565-573	3.8	7
328	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. <i>JAMA Cardiology</i> , 2018 , 3, 225-234	16.2	403
327	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). <i>Circulation</i> , 2018 , 137, 88-90	16.7	19
326	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
325	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 78	3	9
324	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 564-570	6.7	6
323	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018 , 199, 170-175	4.9	4
322	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e3053	7.5	2
321	Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 790-797	18.1	9
320	In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events. <i>Annals of Internal Medicine</i> , 2018 , 168, JC53	8	
319	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 300-310	15.1	39
318	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 798-808	18.1	66
317	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
316	Neighborhood Walkability and Diabetes-Related Complications. <i>Diabetes</i> , 2018 , 67, 309-OR	0.9	2

315	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018 , 41, 348-355	14.6	10
314	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 97-116	5.5	2
313	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	3.9	13
312	Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. <i>Cardiovascular Diabetology</i> , 2018 , 17, 154	8.7	16
311	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018 , 41, 2404-2413	14.6	16
310	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 38-50	1.4	23
309	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017 , 40, e23-e24	14.6	1
308	The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2017 , 14, 345-352	3.3	2
307	Systematic review: Can non-mydriatic cameras accurately detect diabetic retinopathy?. <i>Diabetes Research and Clinical Practice</i> , 2017 , 129, 154-159	7.4	6
306	Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1596-1605	5.6	22
305	The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3218-3225	5.6	5
304	Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2017 , 7, 1629	4.9	4
303	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
302	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 431-437	18.1	258
301	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017 , 2, 370-380	16.2	98
300	Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. <i>Diabetes Care</i> , 2017 , 40, 280-283	14.6	60
299	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
298	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2251-2257	5.6	9

297	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , 2017 , 130, 1465.e27-1465.e39	2.4	10
296	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 877-886	18.1	164
295	Microvascular outcomes in type 2 diabetes - Authors' reply. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 580	18.1	
294	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. <i>Diabetes Research and Clinical Practice</i> , 2017 , 132, 137-143	7.4	
293	Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. <i>CMAJ Open</i> , 2017 , 5, E604-E611	2.5	15
292	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. <i>American Journal of Human Genetics</i> , 2017 , 101, 925-938	11	73
291	Maturation of CGM and Glycemic Measurements Beyond HbA-A Turning Point in Research and Clinical Decisions. <i>Diabetes Care</i> , 2017 , 40, 1611-1613	14.6	18
290	Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans. <i>Scientific Reports</i> , 2017 , 7, 11934	4.9	15
289	ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. <i>Diabetologia</i> , 2017 , 60, 69-80	10.3	54
288	What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. <i>International Journal of Obesity</i> , 2016 , 40, 239-44	5.5	16
287	Sleep quality and risk of diabetes and coronary artery disease among young men. <i>Acta Diabetologica</i> , 2016 , 53, 261-70	3.9	11
286	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016 , 39, 1186-201	14.6	86
285	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 1915-1924	14.6	32
284	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2016 , 6, 18672	4.9	50
283	Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology. <i>Scientific Reports</i> , 2016 , 6, 30744	4.9	4
282	BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. <i>Diabetes Care</i> , 2016 , 39, 1996-2003	14.6	55
281	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016 , 39, 1089-100	14.6	80
280	Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. <i>American Journal of Preventive Medicine</i> , 2016 , 50, 737-745	6.1	3

279	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016 , 39, 701-8	14.6	126
278	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , 2016 , 39, 780-7	14.6	104
277	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , 2016 , 39, 709-16	14.6	48
276	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , 2016 , 7, 138	4.5	2
275	Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population: The INTERHEART Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1863-1865	15.1	15
274	Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight. <i>Pediatrics</i> , 2016 , 138,	7.4	60
273	Making a Difference With Diabetes Research and Care. <i>Diabetes Care</i> , 2016 , 39, 1309-10	14.6	1
272	Toward Fairness in Data Sharing. <i>New England Journal of Medicine</i> , 2016 , 375, 405-7	59.2	67
271	Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. <i>Diabetes Care</i> , 2015 , 38, 22-8	14.6	55
270	Diabetes: Dysglycaemia as a cause of cardiovascular outcomes. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 508-10	15.2	17
269	Risk Prediction for Early CKD in Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1371-9	6.9	66
268	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015 , 36, 1454-62	9.5	83
267	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015 , 170, 117-22	4.9	25
266	Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply. <i>Lancet, The</i> , 2015 , 385, 1180-1	4.0	
265	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015 , 38, 793-800	14.6	82
264	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015 , 28, 995-1009	2.3	13
263	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. <i>Biochemical Journal</i> , 2015 , 468, 125-32	3.8	103
262	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. <i>Human Molecular Genetics</i> , 2015 , 24, 3582-94	5.6	34

261	Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. <i>Toxicology and Applied Pharmacology</i> , 2015 , 285, 32-40	4.6	14
260	Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. <i>Translational Psychiatry</i> , 2015 , 5, e618	8.6	22
259	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015 , 132, 2297-304	16.7	49
258	Coronary artery disease risk among obese metabolically healthy young men. <i>European Journal of Endocrinology</i> , 2015 , 173, 305-12	6.5	15
257	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
256	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015 , 87, 784-91	9.9	50
255	Comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015 , 38, e170-1	14.6	13
254	The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. <i>Journal of Aging Research</i> , 2015 , 2015, 872728	2.3	7
253	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
252	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2682-9	5.6	6
251	Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4409-16	5.6	13
250	Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 82-90		216
249	Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, e1611-8	4.6	28
248	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , 2014 , 57, 738-45	10.3	7
247	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 2242-8a	9.5	34
246	Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. <i>Diabetes Care</i> , 2014 , 37, 1721-8	14.6	179
245	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , 2014 , 57, 1325-31	10.3	39
244	Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial. <i>Diabetes Care</i> , 2014 , 37, 3279-85	14.6	15

243	Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?. <i>Diabetologia</i> , 2014 , 57, 2270-81	10.3	24
242	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. <i>Lancet, The</i> , 2014 , 384, 1936-41	4.0	111
241	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. <i>Diabetologia</i> , 2014 , 57, 2030-7	10.3	9
240	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , 2014 , 37, 1360-6	14.6	67
239	Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. <i>Diabetes Care</i> , 2014 , 37, 604-10	14.6	17
238	Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014 , 37, 634-43	14.6	86
237	Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. <i>Blood Pressure</i> , 2014 , 23, 54-60	1.7	7
236	Diabetes risk among overweight and obese metabolically healthy young adults. <i>Diabetes Care</i> , 2014 , 37, 2989-95	14.6	83
235	Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 553-8	3.2	6
234	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014 , 168, 23-9.e2	4.9	46
233	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 843-51	18.1	214
232	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , 2014 , 174, 458-61	3.2	64
231	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 562-72	18.1	37
230	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014 , 80, 502-7	3.4	36
229	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , 2014 , 120, 564-78	4.3	509
228	Evaluating the feasibility and impact of an internet-based lifestyle management program in a diabetes care setting. <i>Diabetes Technology and Therapeutics</i> , 2014 , 16, 358-62	8.1	7
227	The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Diabetes Care</i> , 2014 , 37, 3244-52	14.6	43
226	Response to Zanders et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , 2014 ;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e223	14.6	

225	Response to Suissa and Azoulay. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e217	14.6	0
224	Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial. <i>Diabetic Medicine</i> , 2014 , 31, 1086-92	3.5	30
223	Willingness to take drugs to prevent serious chronic diseases. <i>Journal of Diabetes</i> , 2014 , 6, 76-80	3.8	1
222	White blood cell subtypes, insulin resistance and β -cell dysfunction in high-risk individuals--the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014 , 81, 536-41	3.4	33
221	Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. <i>JAMA Internal Medicine</i> , 2014 , 174, 324-33	11.5	112
220	Cognitive function and the risk for diabetes among young men. <i>Diabetes Care</i> , 2014 , 37, 2982-8	14.6	41
219	Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 114	2.8	19
218	Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. <i>BMC Health Services Research</i> , 2013 , 13, 71	2.9	11
217	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. <i>Diabetologia</i> , 2013 , 56, 1884-7	10.3	1
216	Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. <i>Diabetes Care</i> , 2013 , 36, 2836-42	14.6	20
215	The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. <i>Molecular Psychiatry</i> , 2013 , 18, 1281-6	15.1	75
214	Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. <i>Atherosclerosis</i> , 2013 , 227, 250-8	3.1	25
213	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 71-8	18.1	30
212	Increased cardiovascular risk after pre-eclampsia in women with dysglycaemia. <i>Diabetic Medicine</i> , 2013 , 30, e1-7	3.5	13
211	Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. <i>Diabetes Care</i> , 2013 , 36, 2162-8	14.6	42
210	Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. <i>JAMA Psychiatry</i> , 2013 , 70, 1041-7	14.5	88
209	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , 2013 , 34, 3137-44	9.5	167
208	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C. <i>Diabetes Care</i> , 2013 , 36, e181	14.6	

207	Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the PROMISE cohort study. <i>Diabetes Care</i> , 2013 , 36, 3599-606	14.6	21
206	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). <i>Diabetes Care</i> , 2013 , 36, 2466-74	14.6	35
205	Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. <i>Reproductive Sciences</i> , 2013 , 20, 1156-61	3	10
204	Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. <i>Diabetes Care</i> , 2013 , 36, 1266-71	14.6	71
203	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. <i>Journal of Hypertension</i> , 2013 , 31, 414-21	1.9	52
202	Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. <i>PLoS ONE</i> , 2013 , 8, e66808	3.7	44
201	Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. <i>International Journal of Clinical Practice</i> , 2012 , 66, 457-64	2.9	29
200	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012 , 55, 36-45	10.3	42
199	Is regression to normoglycaemia clinically important?. <i>Lancet, The</i> , 2012 , 379, 2216-8	40	10
198	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012 , 81, 586-94	9.9	45
197	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
196	Impact of a computerized system for evidence-based diabetes care on completeness of records: a before-after study. <i>BMC Medical Informatics and Decision Making</i> , 2012 , 12, 63	3.6	8
195	Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. <i>Respiratory Medicine</i> , 2012 , 106, 1487-93	4.6	64
194	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 755-64	3.9	57
193	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
192	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. <i>Cardiovascular Revascularization Medicine</i> , 2012 , 13, 95-100	1.6	7
191	Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. <i>Diabetes Care</i> , 2012 , 35, 787-93	14.6	237
190	Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. <i>Diabetes Care</i> , 2012 , 35, 749-53	14.6	18

189	Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. <i>Journal of Nutrition</i> , 2012 , 142, 27-32	4.1	12
188	Basal insulin and cardiovascular and other outcomes. <i>New England Journal of Medicine</i> , 2012 , 367, 1761-2; author reply 1763-4	59.2	11
187	Maternal antioxidants prevent β cell apoptosis and promote formation of dual hormone-expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure. <i>Journal of Diabetes</i> , 2012 , 4, 297-306	3.8	13
186	Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REDuction by Appropriately Targeting Euglycemia) trial. <i>Diabetes Care</i> , 2012 , 35, 19-24	14.6	12
185	Long-term effects of intensive glucose lowering on cardiovascular outcomes. <i>New England Journal of Medicine</i> , 2011 , 364, 818-28	59.2	73 ²
184	Effect of combining rosiglitazone with either metformin or insulin on β cell mass and function in an animal model of Type 2 diabetes characterized by reduced β cell mass at birth. <i>Journal of Diabetes</i> , 2011 , 3, 74-81	3.8	2
183	Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. <i>Journal of Diabetes</i> , 2011 , 3, 232-7	3.8	5
182	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , 2011 , 10, 969-77	24.1	35 ⁶
181	Establishing a relationship between prolactin and altered fatty acid β oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. <i>BMC Cancer</i> , 2011 , 11, 56	4.8	47
180	Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. <i>Quality of Life Research</i> , 2011 , 20, 939-43	3.7	35
179	Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. <i>Diabetologia</i> , 2011 , 54, 230-2	10.3	5
178	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. <i>Diabetologia</i> , 2011 , 54, 487-95	10.3	40
177	Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011 , 6, 92	8.4	154
176	A community-based approach for the self-management of diabetes. <i>European Diabetes Nursing</i> , 2011 , 8, 54-59		1
175	Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 168-75	5.6	95
174	Long-acting risperidone and oral antipsychotics in schizophrenia. <i>New England Journal of Medicine</i> , 2011 , 364, 2265; author reply 265-6	59.2	1
173	Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. <i>Archives of Internal Medicine</i> , 2011 , 171, 1736-44		28
172	Incidence of diabetes following ramipril or rosiglitazone withdrawal. <i>Diabetes Care</i> , 2011 , 34, 1265-9	14.6	28

171	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011 , 32, 581-9	9.5	153
170	Effect of computer-generated tailored feedback on glycemic control in people with diabetes in the community: a randomized controlled trial. <i>Diabetes Care</i> , 2011 , 34, 1794-8	14.6	9
169	Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. <i>Circulation</i> , 2011 , 123, 342-8	16.7	80
168	Prospective associations of vitamin D with β cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. <i>Diabetes</i> , 2011 , 60, 2947-53	0.9	103
167	Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). <i>PLoS ONE</i> , 2011 , 6, e22112	3.7	109
166	Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?. <i>Value in Health</i> , 2010 , 13, 487-94	3.3	99
165	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. <i>Diabetic Medicine</i> , 2010 , 27, 175-80	3.5	33
164	Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. <i>Diabetic Medicine</i> , 2010 , 27, 1226-32	3.5	14
163	Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. <i>Diabetes Care</i> , 2010 , 33, 1629-34	14.6	128
162	Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Diabetes Care</i> , 2010 , 33, 1578-84	14.6	342
161	A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. <i>Diabetes Care</i> , 2010 , 33, 1176-8	14.6	118
160	Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. <i>Circulation</i> , 2010 , 121, 1171-87	16.7	71
159	Macular Edema and Thiazolidinediones Reply. <i>JAMA Ophthalmology</i> , 2010 , 128, 1631		
158	Does insulin therapy promote, reduce, or have a neutral effect on cancers?. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 446-7	27.4	48
157	Long-term consequences of fetal and neonatal nicotine exposure: a critical review. <i>Toxicological Sciences</i> , 2010 , 116, 364-74	4.4	254
156	Effect of Rosiglitazone and Ramipril on β -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. <i>Diabetes Care</i> , 2010 , 33, 608-13	14.6	43
155	Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. <i>Diabetes Care</i> , 2010 , 33, 2250-3	14.6	32
154	Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2010 , 362, 1575-85	59.2	2411

153	Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 1379-81	14.6	240
152	The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. <i>Diabetes Care</i> , 2010 , 33, 1859-64	14.6	217
151	Effects of medical therapies on retinopathy progression in type 2 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 233-44	59.2	859
150	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. <i>BMJ, The</i> , 2010 , 340, b5444	5.9	313
149	Effects of combination lipid therapy in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2010 , 362, 1563-74	59.2	1940
148	Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2390-8	15.1	146
147	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet, The</i> , 2010 , 376, 103-11	40	178
146	More insights on the dysglycaemia-cardiovascular connection. <i>Lancet, The</i> , 2010 , 375, 2195-6	40	24
145	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 297-302	3.8	77
144	Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. <i>JAMA Ophthalmology</i> , 2010 , 128, 312-8		39
143	Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. <i>Diabetologia</i> , 2010 , 53, 1322-30	10.3	21
142	Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. <i>Diabetologia</i> , 2010 , 53, 2509-17	10.3	42
141	Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. <i>Endocrine</i> , 2010 , 37, 303-11	4	5
140	Kidney disease after preeclampsia: a systematic review and meta-analysis. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 1026-39	7.4	141
139	Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. <i>Diabetes Care</i> , 2009 , 32, 221-6	14.6	314
138	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. <i>Journal of Lipid Research</i> , 2009 , 50, 1487-96	6.3	50
137	Dysglycemia and cardiovascular risk in the general population. <i>Circulation</i> , 2009 , 119, 773-5	16.7	18
136	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 270-5	15.2	8

135	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. <i>Cmaj</i> , 2009 , 181, 37-44	3.5	145
134	Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3824-32	5.6	58
133	Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. <i>Circulation</i> , 2009 , 120, 2429-37	16.7	99
132	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , 2009 , 32, 915-20	14.6	49
131	Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2009 , 36, 281-90	4	25
130	Intensive glucose control and macrovascular outcomes in type 2 diabetes. <i>Diabetologia</i> , 2009 , 52, 2288-98	10.3	854
129	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. <i>Diabetes Research and Clinical Practice</i> , 2009 , 83, 387-93	7.4	23
128	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009 , 157, 763-70	4.9	25
127	Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2028-35	15.1	50
126	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet, The</i> , 2009 , 374, 543-50	5.0	191
125	Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 763-71	6.7	21
124	Maternal nicotine exposure increases oxidative stress in the offspring. <i>Free Radical Biology and Medicine</i> , 2008 , 44, 1919-25	7.8	71
123	Effects of intensive glucose lowering in type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 358, 2545-59	59.2	5809
122	Relationship of epicardial fat thickness and fasting glucose. <i>International Journal of Cardiology</i> , 2008 , 128, 424-6	3.2	79
121	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). <i>American Heart Journal</i> , 2008 , 155, 26-32, 32.e1-6	4.9	146
120	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. <i>American Heart Journal</i> , 2008 , 156, 1074-9	4.9	17
119	Dysglycemia and a history of reproductive risk factors. <i>Diabetes Care</i> , 2008 , 31, 1635-8	14.6	20
118	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 276-84	3.3	5

117	The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Archives of Internal Medicine</i> , 2008 , 168, 1699-704		165
116	Increased pancreatic beta-cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mitochondria. <i>Toxicological Sciences</i> , 2008 , 103, 362-70	4.4	57
115	Fetal and neonatal nicotine exposure in Wistar rats causes progressive pancreatic mitochondrial damage and beta cell dysfunction. <i>PLoS ONE</i> , 2008 , 3, e3371	3.7	55
114	Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. <i>Canadian Family Physician</i> , 2008 , 54, 550-8	0.9	24
113	Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 1180-5	5.9	63
112	Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. <i>Schizophrenia Research</i> , 2007 , 96, 215-22	3.6	30
111	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007 , 30, 162-72	14.6	405
110	A family-based intervention to promote healthy lifestyles in an aboriginal community in Canada. <i>Canadian Journal of Public Health</i> , 2007 , 98, 447-52	3.2	62
109	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , 2007 , 99, 4i-20i	3	155
108	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. <i>American Journal of Cardiology</i> , 2007 , 99, 21i-33i	3	385
107	Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , 2007 , 99, 34i-43i	3	125
106	Transgenerational effects of fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2007 , 31, 254-9		45
105	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007 , 3, 798-9		2
104	Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. <i>Journal of Endocrinology</i> , 2007 , 194, 171-8	4.7	64
103	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Circulation</i> , 2007 , 115, 114-26	16.7	552
102	Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 254-8	7.4	44
101	Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 392-7	7.4	31
100	Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 305-12	7.4	384

99	Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. <i>Circulation</i> , 2007 , 115, 1371-5	16.7	146
98	The effects of exercise training on insulin resistance in patients with coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, 803-8		7
97	A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. <i>Diabetes Care</i> , 2007 , 30, 389-94	14.6	224
96	Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> 48:1749-1755. <i>Diabetologia</i> , 2005, 48, 1756-1757	10.3	1
95	Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>American Journal of Kidney Diseases</i> , 2006 , 48, 889-96	7.4	21
94	Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment. <i>Cmaj</i> , 2006 , 174, 25-6	3.5	34
93	Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?. <i>Cmaj</i> , 2006 , 174, 1090-3	3.5	2
92	Diabetes susceptibility. <i>Cmaj</i> , 2006 , 174, 1598-1598	3.5	78
91	Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2006 , 114, 201-8	16.7	199
90	Effect of ramipril on the incidence of diabetes. <i>New England Journal of Medicine</i> , 2006 , 355, 1551-62	59.2	583
89	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet</i> , 2006 , 368, 1096-105	40	1312
88	The DREAM trial [Authors' reply]. <i>Lancet</i> , 2006 , 368, 2050-2051	40	207
87	Preventing type 2 diabetes using combination therapy: design and methods of the CANadian Normoglycaemia Outcomes Evaluation (CANOE) trial. <i>Diabetes, Obesity and Metabolism</i> , 2006 , 8, 531-7	6.7	22
86	A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. <i>Diabetic Medicine</i> , 2006 , 23, 731-42	3.5	167
85	Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes. <i>ACP Journal Club</i> , 2006 , 144, 63		
84	Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 137-54	5.5	13
83	Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. <i>Diabetologia</i> , 2005 , 48, 2661-6	10.3	102
82	Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. <i>Diabetologia</i> , 2005 , 48, 2460-9	10.3	676

81	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> , 2005 , 48, 1749-55	10.3	202
80	The burden of treatment failure in type 2 diabetes: response to Brown et al. <i>Diabetes Care</i> , 2005 , 28, 761-2	14.6	2
79	Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. <i>Circulation</i> , 2005 , 112, 48-53	16.7	185
78	Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. <i>Diabetes Care</i> , 2005 , 28, 1630-5	14.6	236
77	Individualized electronic decision support and reminders can improve diabetes care in the community 2005 , 982	0.7	4
76	Glycemia and Risk for Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2005 , 142, 227	8	
75	Authors' Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3'-Triiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1487-1487	5.6	1
74	Dosage recommendations for combination regimen of thyroxine and 3,5,3'-triiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1486-7; author reply 1487-8	5.6	4
73	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. <i>Diabetes Care</i> , 2004 , 27, 2767	14.6	70
72	Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. <i>Diabetic Medicine</i> , 2004 , 21, 1200-3	3.5	7
71	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. <i>Kidney International</i> , 2004 , 65, 1375-80	9.9	84
70	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. <i>Kidney International</i> , 2004 , S59-62	9.9	56
69	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004 , 47, 1519-27	10.3	139
68	Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3668-76	5.6	328
67	Diagnostic strategies to detect glucose intolerance in a multiethnic population. <i>Diabetes Care</i> , 2003 , 26, 290-6	14.6	63
66	The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. <i>Diabetes Care</i> , 2003 , 26, 144-9	14.6	47
65	Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4551-5	5.6	133
64	Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. <i>Circulation</i> , 2003 , 108, 420-5	16.7	227

63	A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. <i>European Heart Journal Supplements</i> , 2003 , 5, B1-B2	1.5	2
62	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <i>European Heart Journal Supplements</i> , 2003 , 5, A43-A48	1.5	18
61	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 936-42	7.4	62
60	Cardiovascular risk in patients with mild renal insufficiency. <i>Kidney International</i> , 2003 , S192-6	9.9	48
59	Acarbose in the treatment of elderly patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2003 , 59, 37-42	7.4	81
58	Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 641-7	12.7	110
57	Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunction. <i>ACP Journal Club</i> , 2003 , 139, 68		
56	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. <i>Canadian Journal of Cardiology</i> , 2003 , 19, 1387-91	3.8	16
55	Cardiovascular Outcomes and Renal Disease. <i>Annals of Internal Medicine</i> , 2002 , 136, 634	8	4
54	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. <i>Diabetes/Metabolism Research and Reviews</i> , 2002 , 18 Suppl 3, S82-5	7.5	55
53	The value of large, robust trials: the HOPE study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2002 , 19, 29-30		1
52	Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. <i>Diabetes Care</i> , 2002 , 25, 1919-27	14.6	306
51	The economic cost of diabetes in Canada, 1998. <i>Diabetes Care</i> , 2002 , 25, 1303-7	14.6	74
50	Dysglycemia: a key cardiovascular risk factor. <i>Seminars in Vascular Medicine</i> , 2002 , 2, 165-74		13
49	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. The example of albuminuria and the risk of cardiovascular disease in diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2002 , 31, 537-51	5.5	8
48	Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2002 , 2, 157-62	4	22
47	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. <i>Diabetes Research and Clinical Practice</i> , 2002 , 55, 209-19	7.4	120
46	Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. <i>Stroke</i> , 2001 , 32, 2426-32	6.7	1341

45	Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. <i>Annals of Internal Medicine</i> , 2001 , 134, 629-36	8	962
44	Ramipril and the development of diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 1882-5	27.4	390
43	Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 421-6	27.4	1695
42	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). <i>Lancet, The</i> , 2001 , 358, 1147-53	40	215
41	Fußgeschwülle bei Diabetes. <i>Vasa - European Journal of Vascular Medicine</i> , 2001 , 30, 233-237	1.9	
40	The plasma glucose level—a continuous risk factor for vascular disease in both diabetic and non-diabetic people. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 498, 35-9	3.6	3
39	Perceived exertion with glucose ingestion in adolescent males with IDDM. <i>Medicine and Science in Sports and Exercise</i> , 2000 , 32, 167-73	1.2	20
38	Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. <i>Diabetes Care</i> , 2000 , 23, 377-80	14.6	31
37	The HOPE study and diabetes. <i>Lancet, The</i> , 2000 , 355, 1183-1184	40	18
36	Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. <i>Lancet, The</i> , 2000 , 355, 773-8	40	1643
35	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. <i>Lancet, The</i> , 2000 , 355, 253-259	40	2668
34	Miglitol, an αglucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. <i>Nutrition Research</i> , 2000 , 20, 1447-1456	4	16
33	Searching for answers to ethnic disparities in cardiovascular risk. <i>Lancet, The</i> , 2000 , 356, 266-7	40	22
32	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). <i>Lancet, The</i> , 2000 , 356, 279-84	40	748
31	Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. <i>Circulation</i> , 2000 , 102, 1014-9	16.7	598
30	A controlled evaluation of a national continuing medical education programme designed to improve family physicians' implementation of diabetes-specific clinical practice guidelines. <i>Diabetic Medicine</i> , 1999 , 16, 964-9	3.5	26
29	Summary of randomized trials of angiotensin converting enzyme inhibitors. <i>Clinical and Experimental Hypertension</i> , 1999 , 21, 835-45	2.2	16
28	Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. <i>Canadian Journal of Physiology and Pharmacology</i> , 1999 , 77, 118-123	2.4	35

27	Preventive medicine in a diabetes clinic: an opportunity to make a difference. <i>Lancet, The</i> , 1999 , 353, 606-8	40	6
26	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 612-9	15.1	75
25	The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. <i>Diabetes Care</i> , 1999 , 22, 233-40	14.6	1355
24	Dysglycaemia: a cardiovascular risk factor. <i>Diabetes Research and Clinical Practice</i> , 1998 , 40 Suppl, S9-14	7.4	10
23	Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus. <i>Evidence-based Cardiovascular Medicine</i> , 1998 , 2, 23-24		
22	Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3169-3176	5.6	67
21	The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. <i>Canadian Journal of Cardiology</i> , 1998 , 14, 1349-57	3.8	28
20	Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. <i>Endocrine Journal</i> , 1997 , 44, 367-74	2.9	37
19	Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. <i>Diabetes Care</i> , 1996 , 19, 1225-8	14.6	55
18	Risk factors for acute myocardial infarction in Indians: a case-control study. <i>Lancet, The</i> , 1996 , 348, 358-63	40	203
17	Dysglycaemia and risk of cardiovascular disease. <i>Lancet, The</i> , 1996 , 347, 949-50	40	134
16	A new mutation in the thyroid hormone receptor (TR) beta gene (V458A) in a family with resistance to thyroid hormone (RTH). <i>Thyroid</i> , 1996 , 6, 311-2	6.2	9
15	Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. <i>Journal of General Internal Medicine</i> , 1996 , 11, 744-9	4	172
14	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995 , 273, 1610	27.4	83
13	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995 , 274, 1800	27.4	477
12	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 389	27.4	553
11	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 272, 1367	27.4	399
10	Spectrum of quality of life impairment in hypothyroidism. <i>Quality of Life Research</i> , 1994 , 3, 323-7	3.7	58

9	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 59	27.4	379
8	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 703	27.4	1292
7	Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. <i>Annals of Internal Medicine</i> , 1993 , 118, 419-23	8	124
6	How common is postpartum thyroiditis? A methodologic overview of the literature. <i>Archives of Internal Medicine</i> , 1990 , 150, 1397-1400		28
5	Separate induction of MHC and thyroid microsomal antigen (McAg) expression on thyroid cell monolayers: enhancement of lectin-induced McAg expression by interferon-gamma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987 , 64, 1302-8	5.6	9
4	Immunomodulatory effect of the treatment of Graves' disease on antigen-specific monocyte procoagulant activity production. <i>Clinical Endocrinology</i> , 1987 , 27, 321-30	3.4	2
3	Thyocyte HLA-DR expression and interferon-gamma production in autoimmune thyroid disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 63, 695-708	5.6	98
2	Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test. <i>Journal of Endocrinological Investigation</i> , 1986 , 9, 471-8	5.2	4
1	Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis		3